Squarepoint’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Squarepoint’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,769	Closed	-$2.16M	–	4171
2023 Q1	$2.16M	Sell	23,769 -65,515	-73%	-$3.84M	0.01%	1376
2022 Q4	$3.39M	Buy	89,284 +48,065	+117%	+$1.65M	0.01%	1042
2022 Q3	$1.04M	Buy	41,219 +18,044	+78%	+$500K	0.01%	1750
2022 Q2	$704K	Buy	+23,175	New	+$691K	﹤0.01%	1818
2022 Q1	–	Sell	-74,679	Closed	-$1.97M	–	3731
2021 Q4	$1.97M	Buy	74,679 +54,683	+273%	+$4.23M	0.01%	1271
2021 Q3	$2.01M	Buy	19,996 +13,052	+188%	+$1.53M	0.01%	1197
2021 Q2	$983K	Sell	6,944 -671	-9%	-$75.8K	﹤0.01%	1640
2021 Q1	$759K	Buy	7,615 +5,112	+204%	+$596K	﹤0.01%	1726
2020 Q4	$309K	Buy	+2,503	New	+$329K	﹤0.01%	2186
2020 Q3	–	Sell	-6,648	Closed	-$1.04M	–	2942
2020 Q2	$1.04M	Buy	+6,648	New	+$1.01M	0.02%	921
2020 Q1	–	Sell	-19,751	Closed	-$4.04M	–	2695
2019 Q4	$4.04M	Buy	19,751 +15,732	+391%	+$2.87M	0.02%	577
2019 Q3	$323K	Sell	4,019 -3,481	-46%	-$295K	﹤0.01%	1856
2019 Q2	$708K	Sell	7,500 -2,080	-22%	-$180K	0.01%	1460
2019 Q1	$819K	Sell	9,580 -11,025	-54%	-$915K	0.01%	1199
2018 Q4	$1.16M	Buy	20,605 +8,155	+66%	+$498K	0.01%	866
2018 Q3	$1.02M	Buy	+12,450	New	+$877K	0.01%	978
2018 Q2	–	Sell	-33,000	Closed	-$677K	–	2133
2018 Q1	$677K	Buy	33,000 +17,566	+114%	+$452K	0.01%	970
2017 Q4	$437K	Buy	+15,434	New	+$431K	0.01%	1291

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's RETA Position: Q2 2023 in Review

Squarepoint sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 23,769 shares — an estimated $2.16M sold.

Squarepoint first reported a position in RETA in Q4 2017 and held it in 18 quarters. The position peaked at $4.04M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Squarepoint reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Squarepoint sold 23,769 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $2.16M.
Squarepoint first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 18 quarters.
Squarepoint's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.04M in Q4 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.